Search results
Showing 76 to 90 of 90 results for adalimumab
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 199.
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)
This guidance has been updated and replaced by NICE technology appraisal guidance 383.
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)
This guidance has been updated and replaced by NICE technology appraisal guidance 329.
Discontinued [GID-TAG402]
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA
risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with...
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today